Physician profile
Katherine Elizabeth Cornforth
NPI 1366760548
$4,734.52
in general payments reported to CMS, 2019-2025
29 companies · $1,170 in 2025
The $1,170 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $638 · 2020: $276 · 2021: $634 · 2022: $848 · 2023: $499 · 2024: $670 · 2025: $1,170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,999 · Education: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,999.20 |
| Education | $340.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,072.39 | 2019-2023 | Lo Loestrin Fe, Liletta |
| Daiichi Sankyo INC. | $587.47 | 2019-2025 | Injectafer |
| Astellas Pharma US INC | $524.72 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $395.53 | 2023-2025 | |
| Exeltis, USA INC. | $363.07 | 2019-2025 | Slynd |
| Agile Therapeutics, INC. | $308.11 | 2021-2024 | Twirla |
| Sumitomo Pharma America, INC. | $136.74 | 2023-2025 | Myfembree |
| Evofem Biosciences, INC. | $120.52 | 2020-2025 | Phexxi, Solosec, Phexx |
| Organon LLC | $118.71 | 2022-2024 | |
| Millicent US INC | $113.49 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Therapeuticsmd, INC. | $113.20 | 2019-2022 | |
| Mylan Pharmaceuticals INC. | $110.89 | 2019-2022 | |
| Pfizer INC. | $92.83 | 2019-2023 | |
| Avion Pharmaceuticals | $88.68 | 2019-2023 | Balcoltra |
| Myovant Sciences INC. | $86.32 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $72.53 | 2019-2020 | |
| Acessa Health INC. | $65.32 | 2019-2020 | |
| Duchesnay USA Incorporated | $55.76 | 2019 | |
| Coopersurgical, INC. | $51.87 | 2020-2024 | Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $43.84 | 2021-2022 | |
| Allergan, INC. | $36.98 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $33.88 | 2020-2021 | |
| Hologic Sales and Service, LLC | $32.97 | 2020-2025 | Aptima |
| Minerva Surgical, INC | $22.61 | 2019 | |
| Shield Therapeutics INC | $21.50 | 2022 | |
| Meditrina | $19.92 | 2022 | |
| Aspira Women'S Health INC | $15.22 | 2024 | Ova1 |
| Covidien LP | $14.75 | 2019 | |
| Davol INC. | $14.70 | 2023 | Arista Ah Flexitip |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Cornforth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.